OBJECTIVE: To improve medication adherence by reducing self-reported adherence barriers, and to identify medication discrepancies by comparing physician-prescribed and patient-reported medical regimens. DESIGN: Prospective, randomized, controlled trial. SETTING AND PARTICIPANTS: A single academically affiliated community health center. Eligible patients had type 2 diabetes, had undergone laboratory testing in the year preceding the study, and had visited the clinic in the 6 months preceding the study. INTERVENTION: A pharmacist administered detailed questionnaires, provided tailored education regarding medication use and help with appointment referrals, and created a summary of adherence barriers and medication discrepancies that was entered into the medical record and electronically forwarded to the primary care provider. MEASUREMENTS: Changes in self-reported adherence rates and barriers were compared 3 months after the initial interview. Intervention patients with medication discrepancies at baseline were assessed for resolution of discrepancies at 3 months. RESULTS:Rates of self-reported medication adherence were very high and did not improve further at 3 months (6.9 of 7 d, with all medicines taken as prescribed; p = 0.3). Medical regimen discrepancies were identified in 44% of intervention patients, involving 45 doses of medicines. At 3-month follow-up, 60% of discrepancies were resolved by corrections in the medical record, while only 7% reflected corrections by patients. CONCLUSIONS: In this community cohort, patients reported few adherence barriers and very high medication adherence rates. Our patient-tailored intervention did not further reduce these barriers or improve self-reported adherence. The high prevalence of medication discrepancies appeared to mostly reflect inaccuracies in the medical record rather than patient errors.
RCT Entities:
OBJECTIVE: To improve medication adherence by reducing self-reported adherence barriers, and to identify medication discrepancies by comparing physician-prescribed and patient-reported medical regimens. DESIGN: Prospective, randomized, controlled trial. SETTING AND PARTICIPANTS: A single academically affiliated community health center. Eligible patients had type 2 diabetes, had undergone laboratory testing in the year preceding the study, and had visited the clinic in the 6 months preceding the study. INTERVENTION: A pharmacist administered detailed questionnaires, provided tailored education regarding medication use and help with appointment referrals, and created a summary of adherence barriers and medication discrepancies that was entered into the medical record and electronically forwarded to the primary care provider. MEASUREMENTS: Changes in self-reported adherence rates and barriers were compared 3 months after the initial interview. Intervention patients with medication discrepancies at baseline were assessed for resolution of discrepancies at 3 months. RESULTS: Rates of self-reported medication adherence were very high and did not improve further at 3 months (6.9 of 7 d, with all medicines taken as prescribed; p = 0.3). Medical regimen discrepancies were identified in 44% of intervention patients, involving 45 doses of medicines. At 3-month follow-up, 60% of discrepancies were resolved by corrections in the medical record, while only 7% reflected corrections by patients. CONCLUSIONS: In this community cohort, patients reported few adherence barriers and very high medication adherence rates. Our patient-tailored intervention did not further reduce these barriers or improve self-reported adherence. The high prevalence of medication discrepancies appeared to mostly reflect inaccuracies in the medical record rather than patient errors.
Authors: Marilyn D Ritholz; Elizabeth A Beverly; Martin J Abrahamson; Kelly M Brooks; Brittney A Hultgren; Katie Weinger Journal: Diabetes Educ Date: 2011-10-14 Impact factor: 2.140
Authors: Alison E Fohner; Dilrini K Ranatunga; Khanh K Thai; Brian L Lawson; Neil Risch; Akinyemi Oni-Orisan; Aline T Jelalian; Allan E Rettie; Vincent X Liu; Catherine A Schaefer Journal: Pharmacogenet Genomics Date: 2019-10 Impact factor: 2.089
Authors: Marya J Cohen; Shimon Shaykevich; Courtney Cawthon; Sunil Kripalani; Michael K Paasche-Orlow; Jeffrey L Schnipper Journal: J Hosp Med Date: 2012-04-02 Impact factor: 2.960
Authors: Sarah L Cutrona; Niteesh K Choudhry; Margaret Stedman; Amber Servi; Joshua N Liberman; Troyen Brennan; Michael A Fischer; M Alan Brookhart; William H Shrank Journal: J Gen Intern Med Date: 2010-05-13 Impact factor: 5.128
Authors: T Alafia Samuels; Shari Bolen; H C Yeh; Marcela Abuid; Spyridon S Marinopoulos; Jonathan P Weiner; Maura McGuire; Frederick L Brancati Journal: J Gen Intern Med Date: 2008-09-12 Impact factor: 5.128
Authors: Joni L Strom Williams; Rebekah J Walker; Brittany L Smalls; Jennifer A Campbell; Leonard E Egede Journal: Diabetes Manag (Lond) Date: 2014-01-01